HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS CONFERENCE CALENDAR
LATEST UPDATES » Volume 20, No. 8, August 2016 – Novel Technologies for Antibody Drug Discovery in Japan       » Global Experts Convene to Discuss China's Plan for Diabetes Prevention and Rehabilitation in 2016       » Butterflies Offer Climate Scientists Ecological Insights       » Thermal Stability of Camelid Single Domain VHH Antibody       » That Gut Feeling: How A Healthy Digestive System Has Everything To Do With It       » World Heart Day - At the Heart of Health      
BIOBOARD - NORTH AMERICA
Protein helps colon cancer move and invade
Previous studies show that the km23-1 protein is involved in the movement of cancer cells and in the control of specific proteins at the leading edge of moving cells. A new study shows that km23-1 is used in the cancer cell's ability to move out of a tumor in the early stages of invasion.

“Km23-1 may be able to help in this process due to its role in the assembly of large groups of proteins favorable to cancer invasion,” says Kathleen Mulder, Professor of Biochemistry and Molecular Biology at Penn State.

The researchers limited the amount of km23-1 available in the cells they studied, which allowed them to see how it affects cell behavior.

A reduction in km23-1 caused a decrease in the production of transforming growth factor beta (TGF-beta). In healthy cells, TGF-beta helps prevent cancer growth. However, in cancer cells, the protein actually aids in the spread of tumors. Limiting the protein also blocks the activity of proteins previously shown to lead to TGF-beta production.

In the study, reported in the journal PLOS ONE, the researchers also show that cells with less km23-1 have reduced amounts of a protein that forms a framework structure associated with the spread of cancer. This scaffolding holds together key factors that help the cancer cells move and invade to form secondary tumors.

By decreasing km23-1, colon cancer cells do not spread as much. This also affects several proteins known to make a cancer cell invasive, demonstrating that the protein is an important potential target for cancer therapies.

The researchers also looked at another protein that influences cell survival, migration, and invasion, called ERK, which has higher activity in cancer cells. Lowering the levels of km23-1, reduced ERK activation. Decreased ERK activity relates to the production of TGF-beta and cell movement.

“If we can block km23-1, we can stop the spread of colon cancer earlier,” Mulder says. “But we would also affect other important functions of the protein. In order to address this issue, we are now trying to find the specific partners of km23-1 that contribute to the invasion of the cancer cells. Then we can design more precise therapeutic agents that target critical regions of km23-1 rather than eliminating the entire protein.”

Researchers used a cell model that represents a unique class of colon cancer that needs further study. The model features cells that move as groups, and not singularly.

“The type of cell movement, or migration, has important implications with respect to the detection of tumor cells in the blood of cancer patients, as well as for the development of new treatments,” Mulder says.

The National Institutes of Health and, in part, a Pennsylvania Department of Health CURE grant supported this study.

Source: Penn State

Click here for the complete issue.

NEWS CRUNCH  
news CPhI's Pre-Connect Congress outlines current trends in pharma
news World Population Day 2016
news NUS Student Clinches Top Prize at National Smart Mapping Competition with Cutting-Edge Food Security Solution
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  

Lady Ganga: Nilza'S Story
COLUMNS  
Subscribe to APBN E-Newsletter
Find us under 'Others' option to receive APBN e-newsletters thrice a month!

APBN Editorial Calendar 2016
January:
Guest Editorial - Biotechnology In Korea
February:
Guest Editorial - Biomedical Research Governance
March:
Guest Editorial - Life-Saving Opportunities: A Guide to Regenerative Medicine
April:
Leading-Edge ONCOLOGY
May:
Healthcare Systems & Policies in Asia
June:
Medical Devices & Healthcare Technology
July:
Water Technology and Management
August:
Novel Technologies for Antibody Drug Discovery in Japan
September:
Infectious Diseases
October:
Medical Tourism
November:
Big Data in Healthcare
December:
Evidence-based TCM
Editorial calendar is subjected to changes.
– Editor: Carmen, Jia Wen Loh
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Carmen
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com or Mr Edward
Copyright© 2016 World Scientific Publishing Co Pte Ltd  •  Privacy Policy